Clinical ResearchClinical Evaluation of a Paclitaxel-Eluting Balloon for Treatment of Femoropopliteal Arterial Disease: 12-Month Results From a Multicenter Italian Registry
Under an Elsevier user license
open archive
Key Words
femoropopliteal artery
ischemic vascular disease
paclitaxel-eluting balloon(s)
restenosis
Abbreviations and Acronyms
ABI
ankle-brachial index
ACD
absolute claudication distance
PEB
paclitaxel-eluting balloon(s)
PSVR
peak systolic velocity ratio
PTA
percutaneous transluminal angioplasty
QOL
quality of life
SFA
superficial femoral artery
TLR
target lesion revascularization
Cited by (0)
Dr. Micari is a Medtronic consultant. Drs. Castriota and Cremonesi have reported relationships with Medtronic, Invatec, and Boston Scientific. Dr. Biamino is a consultant for Spectranetics and Igaki; and is proctor for Proctor EV3 and Hexacath. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Copyright © 2012 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.